ENGLEWOOD, Colo., July 17, 2024 /PRNewswire/ -- Zynex, Inc. (NASDAQ: ZYXI), an innovative medical technology company specializing in the manufacture and sale of non-invasive medical devices for pain management, rehabilitation, and patient monitoring, will hold a conference call on Thursday, July 25, 2024 at 4:15 PM Eastern Time to discuss its financial results for the second quarter ended June 30, 2024. Financial results will be issued in a press release prior to the call.
Zynex management will host the conference call, followed by a question and answer session.
Date: Thursday, July 25, 2024
Time: 4:15 PM Eastern Time (2:15 PM Mountain Time)
U.S. & Canada dial-in number: 800-930-7718
International number: 646-394-9830
Webcast: 2Q 2024 Webcast Link
The Company will also provide a link at https://zynexmed.investorroom.com/ for those who wish to stream the call via webcast. Please call the conference telephone number 5-10 minutes prior to the start time.
About Zynex, Inc.
Zynex, founded in 1996, develops, manufactures, markets, and sells medical devices used for pain management and rehabilitation as well as non-invasive fluid, sepsis, and laser-based pulse oximetry monitoring systems for use in hospitals. For additional information, please visit: www.zynex.com.
Investor Relations Contact:
Quinn Callanan, CFA or Brian Prenoveau, CFA
MZ Group – MZ North America
This email address is being protected from spambots. You need JavaScript enabled to view it.
+949 694 9594
Last Trade: | US$2.27 |
Daily Change: | -0.03 -1.30 |
Daily Volume: | 35,738 |
Market Cap: | US$72.300M |
April 29, 2025 December 12, 2024 December 05, 2024 |
Recursion Pharmaceuticals is a clinical stage TechBio company leading the space by decoding biology to industrialize drug discovery. Enabling its mission is the Recursion OS, a platform built across diverse technologies that continuously expands one of the world’s largest....
CLICK TO LEARN MORECompass Therapeutics is a clinical-stage, oncology-focused biopharmaceutical company developing proprietary antibody-based therapeutics to treat multiple human diseases. The company's scientific focus is on the relationship between angiogenesis, the immune system, and tumor growth...
CLICK TO LEARN MOREEnd of content
No more pages to load